SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Robotic hand touching molecules. 3d illustration f
IN PARTNERSHIP WITH CHARLES RIVER LABORATORIES
AI in CAR T Development: Lessons From the Front Lines
While the benefits of AI are clear, the amount data sets needed for effective AI integration is proving to be a challenge. This is particularly true for cell therapy companies as they are eagerly seeking ways to reduce development costs. Two experts at Charles River Laboratories provide insights by giving their takeaways from their own AI integrations.
October 13, 2025
 · 
5 min read
 · 
BioSpace Insights
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Opinion
Can AI Clinical Trial Technology Deliver on Its Promise?
To drive true innovation in drug development, executives must not let excitement about the latest shiny object obscure ultimate outcomes.
October 13, 2025
 · 
4 min read
 · 
Jason Housley
Same goal. Two businesses on the growth graph. vector
FDA
Consistency in the Chaos: FDA Approvals Within Average Range as Q4 Kicks Off
Heading into the final quarter of a year that has seen dramatic upheaval at the FDA—from the exodus of numerous senior leaders to unclear policy changes and a safety saga that engulfed the gene therapy space—drug approvals appear roughly on par with recent years.
October 13, 2025
 · 
4 min read
 · 
Heather McKenzie
Isometric Business people pushing cubes. Winner easily moving the cube. Winning strategy, efficiency, innovation in business concept
Rare Diseases
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause
Therapies from industry leaders BioMarin and Ascendis Pharma supply a key hormone that promotes bone growth. In order to move the field forward, challengers are looking to address the underlying cause of the rare, genetic disease.
October 13, 2025
 · 
7 min read
 · 
Tristan Manalac
Facade of AstraZeneca's office in Shanghai, China
Drug pricing
AstraZeneca Becomes Second Pharma to Strike DTC Deal With Trump Administration
The British pharmaceutical giant has joined the direct-to-consumer push, following Pfizer and Amgen’s announcements in response to the president’s calls to lower U.S. drug prices.
October 10, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
South side and Dome of the US Capitol in Washington DC, United States
BIOSECURE Act
The BIOSECURE Act Is Back, as Congress Tacks New Version On to Broader Defense Bill
A new version of the controversial bill removes the specific company names that were included in a previous iteration but still requires the industry to ditch Chinese biotech contractors in order to receive federal dollars.
October 10, 2025
 · 
1 min read
 · 
Annalee Armstrong
External view of Bristol Myers Squibb's office California
Mergers & acquisitions
BMS Makes $1.5B Cell Therapy Play With Orbital Takeover
Investor reaction to the deal was muted, with BMO Capital Markets analysts saying they “continue to look for more” from Bristol Myers Squibb before they can “get excited about the near term turnaround story.”
October 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Business negotiation and cooperation vector concept. Symbol of a deal, handshake, success. Minimal design eps10 illustration.
Gene therapy
AviadoBio Looks to China for Eye-Based Gene Therapy in $413M UgeneX Pact
AviadoBio will have the option to exclusively license UGX-202, a vision-restoring gene therapy for the rare eye condition retinitis pigmentosa.
October 10, 2025
 · 
2 min read
 · 
Tristan Manalac
President Donald Trump signs S.1852, The GENIUS Act, Friday, July 18, 2025, in the East Room of the White House. (Official White House Photo by Daniel Torok)
Drug pricing
GoodRx Wants In on Direct-to-Consumer TrumpRx Platform
GoodRx, an online platform that offers drug discount coupons to patients, is in talks with the government to participate in the forthcoming TrumpRx program.
October 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS